Hess David A, Bonde Jesper, Craft Timothy P, Wirthlin Louisa, Hohm Sarah, Lahey Ryan, Todt Laura M, Dipersio John F, Devine Steven M, Nolta Jan A
Department of Internal Medicine, Division of Oncology, Hematopoietic Development and Malignancy Group, Washington University School of Medicine, 4940 Parkview Place, St. Louis, MO 63110, USA.
Biol Blood Marrow Transplant. 2007 Apr;13(4):398-411. doi: 10.1016/j.bbmt.2006.12.445.
AMD3100 inhibits the interaction between SDF-1 and CXCR4, and rapidly mobilizes hematopoietic progenitors for clinical transplantation. However, the repopulating function of human cells mobilized with AMD3100 has not been characterized in comparison to cells mobilized with granulocyte-colony stimulating factor (G-CSF) in the same donor. Therefore, healthy donors were leukapheresed 4 hours after injection with AMD3100; after 10 days of drug clearance the same donor was mobilized with G-CSF, allowing a paired comparison of repopulation by mobilized cells. Transplantation of mononuclear cells (MNC) or purified CD34(+) cells was compared at limiting dilution into NOD/SCID mice. Human AMD3100-mobilized MNC possessed enhanced repopulating frequency in comparison to G-CSF-mobilized MNC from paired donors, and purified CD34(+) progenitors were at least as efficient as the G-CSF mobilized cells. The frequencies of NOD/SCID repopulating cells (SRC) were 1 SRC in 8.7 x 10(6) AMD3100-mobilized MNC compared to 1 SRC in 29.0 x 10(6) G-CSF-mobilized MNC, and 1 SRC in 1.2 x 10(5) AMD3100-mobilized CD34(+) cells compared to 1 SRC in 1.8 x 10(5) G-CSF-mobilized CD34(+) cells. Hematopoietic differentiation of transplanted progenitors was similar after AMD3100 or G-CSF-mobilization. Thus, AMD3100 mobilized peripheral blood represents a rapidly obtained, highly repopulating source of hematopoietic progenitors for clinical transplantation.
AMD3100可抑制基质细胞衍生因子-1(SDF-1)与CXC趋化因子受体4(CXCR4)之间的相互作用,并能迅速动员造血祖细胞用于临床移植。然而,与同一供体中用粒细胞集落刺激因子(G-CSF)动员的细胞相比,用AMD3100动员的人细胞的再增殖功能尚未得到表征。因此,在注射AMD3100后4小时对健康供体进行白细胞单采;在药物清除10天后,用G-CSF对同一供体进行动员,以便对动员细胞的再增殖进行配对比较。将单核细胞(MNC)或纯化的CD34(+)细胞以有限稀释度移植到NOD/SCID小鼠体内进行比较。与配对供体中G-CSF动员的MNC相比,人AMD3100动员的MNC具有更高的再增殖频率,并且纯化的CD34(+)祖细胞至少与G-CSF动员的细胞一样有效。NOD/SCID再增殖细胞(SRC)的频率在8.7×10(6)个AMD3100动员的MNC中为1个SRC,而在29.0×10(6)个G-CSF动员的MNC中为1个SRC;在1.2×10(5)个AMD3100动员的CD34(+)细胞中为1个SRC,而在1.8×10(5)个G-CSF动员的CD34(+)细胞中为1个SRC。AMD3100或G-CSF动员后,移植祖细胞的造血分化相似。因此,AMD3100动员的外周血是一种可快速获得的、具有高再增殖能力的造血祖细胞来源,可用于临床移植。